Antibodies, a pharmaceutical composition and kit comprising the same, and uses thereof

TWI942774BActive Publication Date: 2026-10-21MYTHIC THERAPEUTICS INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
TW111104390
Authority / Receiving Office
TW · TW
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-02-03
Filing Date
2022-02-07
Publication Date
2026-10-21
Estimated Expiration
2042-02-06

AI Technical Summary

Technical Problem

There is a need for improved antibody-drug conjugates that exhibit enhanced efficacy in target mammalian cells, particularly in terms of increased killing and endolysosomal delivery.

Method used

The development of antibodies with specific heavy and light chain variable regions, including amino acid substitutions and deletions, such as cysteine substitutions at position 105 and deletions at positions 106 and 108, and other specific modifications, to enhance cytotoxicity and endolysosomal delivery.

Benefits of technology

The modified antibodies demonstrate increased cytotoxicity and endolysosomal delivery, leading to enhanced target mammalian cell killing and toxin release, with potential applications in cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure TWG2TB001916510_001
    Figure TWG2TB001916510_001
  • Figure TWG2TB001916510_002
    Figure TWG2TB001916510_002
  • Figure TWG2TB001916510_003
    Figure TWG2TB001916510_003
Patent Text Reader

Abstract

This document provides an antibody that specifically binds to MET and includes a heavy chain variable region and a light chain variable region having the sequences shown herein, and the heavy chain having the configuration shown herein. This document also provides pharmaceutical compositions comprising an effective amount of the antibody, kits comprising at least one dose of the antibody or pharmaceutical composition, and their therapeutic uses.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Method of screening an antibody

    US20160161500A1

  • ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE

    WO2017201204A1

  • DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF

    WO2019189453A1